



Company Fact Sheet

Headquarters:

Biodesix Inc.
2970 Wilderness Avenue, Suite 100
Boulder, CO 80301
USA

Other Locations:

Biodesix Laboratory
8960 Commerce Dr
De Soto, KS 66018
USA

Number of Employees:

150+

Biodesix:

A leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease.

Technologies:

Our core belief is that no single technology will answer all clinical questions that we encounter. Therefore, we employ multiple technologies, including genomics, transcriptomics, proteomics, and radiomics, and leverage our proprietary AI platform, the Diagnostic Cortex[®], to discover innovative diagnostic tests for clinical use. We believe we are unique in the diagnostics market as this approach allows for a broader and more holistic understanding of each patient's disease state. Our data-driven and technology agnostic approach is designed to enable us to discover diagnostic tests that answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies.

Lung-Focused Diagnostics:

Nodify Lung™ consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2[®] tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.

Biodesix Lung Reflex[®] testing consists of the GeneStrat[®] tumor profiling test and the VeriStrat[®] immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.

The **Biodesix WorkSafe™ COVID-19 Testing Program** consists of two EUA-FDA tests: the Bio-Rad SARS-CoV-2 ddPCR molecular test for active infection and the Platelia SARS-CoV-2 Total Antibody serology test for prior infection.



Biopharma Services:

We provide our biopharmaceutical customers and academic partners with testing services for diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.

Lab Certifications:

CAP, CLIA, COLA, ISO 13485, and NYS CLEP-accredited as well as complying with all applicable regulatory and state agency requirements holding state permits and licenses in California, Florida, Maryland, New York, Pennsylvania, Rhode Island, and Washington.

Intellectual Property:

82 issued patents and 33 registered trademark numbers

Partnerships:

50+ biopharmaceutical customers and academic research partners

Media Resources:

Scott Hutton, Chief Executive Officer
Robin Harper Cowie, Chief Finance Officer
Bobbi Coffin, Chief Growth Officer

#